EGFR and neoplasm: Moreover, in view of recent results of the ADAURA study [45] demonstrating the efficacy of osimertinib in EGFR mutated resected NSCLC it will become essential to detect EGFR mutation using highly sensitive methodologies, as the releasing of cftDNA in early stage tumor could be very low, leading to the necessity to use methodologies with a very low limit of detection.